Destiny Pharma Plc has decided to exit the AIM market of the London Stock Exchange and go private in order to raise money for the Phase 3 development of its lead antibiotic product XF-73 Nasal. The wholly-owned product delivered promising data in a Phase 2 study and has been poised for the next stage pending a licensing partner.
